Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01746810 · ClinicalTrials.gov registry record · Phase 1
IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01746810 is a Phase 1 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 1 participants.
The verdict
NCT01746810, a Phase 1 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with ablation therapy in treating patients with non-small cell lung cancer or lung metastases. Ablation therapy, such as radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Ablation therapy, such as microwave ablation kills tumor cells by heating them to several degrees above normal body temperature. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving ablation therapy together with stereotactic body radiation therapy may kill more tumor cells.
Interventions
- RADIATION Stereotactic body RT and IRGA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01746810
The ClinicalTrials.gov registry entry for NCT01746810 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic body RT and IRGA is the first listed.
NCT01746810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01746810 about?
NCT01746810 is a clinical study titled "IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors". This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with ablation therapy in treating patients with non-small cell lung cancer or lung metastases. Ablation therapy, such as radiofrequency ablation uses a high-frequency, electric curren...
What is the current status of trial NCT01746810?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-07. Estimated completion is 2015-10-13.
What interventions are being tested in trial NCT01746810?
The interventions under investigation include: Stereotactic body RT and IRGA (RADIATION).
Who is sponsoring clinical trial NCT01746810?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.